Molecular Partners AG (XSWX:MOLN) Net Margin %

: -1,916.67% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Molecular Partners AG's Net Income for the three months ended in Dec. 2023 was CHF-19.78 Mil. Molecular Partners AG's Revenue for the three months ended in Dec. 2023 was CHF1.03 Mil. Therefore, Molecular Partners AG's net margin for the quarter that ended in Dec. 2023 was -1,916.67%.

The historical rank and industry rank for Molecular Partners AG's Net Margin % or its related term are showing as below:

XSWX:MOLN' s Net Margin % Range Over the Past 10 Years
Min: -880.71 Med: -152.54 Max: 62.17
Current: -880.71

XSWX:MOLN's Net Margin % is ranked worse than
71.47% of 1027 companies
in the Biotechnology industry
Industry Median: -164.06 vs XSWX:MOLN: -880.71

Molecular Partners AG Net Margin % Historical Data

The historical data trend for Molecular Partners AG's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-178.03

-671.70

-683.65

62.17

-880.70

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-647.23	-484.52	-3,852.29	-450.18	-1,916.67

Competitive Comparison

For the Biotechnology subindustry, Molecular Partners AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Net Margin % distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Net Margin % falls into.

Molecular Partners AG Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Molecular Partners AG's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-61.984	/	7.038
	=	-880.70 %

Molecular Partners AG's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-19.78	/	1.032
	=	-1,916.67 %

Molecular Partners AG (XSWX:MOLN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Molecular Partners AG Net Margin % Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.